Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway found a 45% lower risk in patients taking these medications. The drugs may ...

A new study found that semaglutides like Ozempic are linked to a lower risk of Alzheimer's disease and dementia. Below, a neurologist explains the connection.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Ozempic use is associated with a lowered risk for cognitive problems, researchers in a new study said. The findings, however, cannot be applied to users who do not have diabetes. The study ...

Ozempic linked to lower dementia rate in Oxford study After a year on the drug, patients had a 48% lower risk of dementia compared with those who’d taken sitagliptin.

A new scientific study has found that weight loss jabs such as Mounjaro and Ozempic can help protect against serious health ...

Ozempic may lower dementia and nicotine dependence risk in people with type 2 diabetes. A recent study shows fewer cognitive deficits and lower smoking rates compared with other diabetes drugs.

Novo Nordisk A/S’s Ozempic was linked to lower rates of dementia and a range of other mental problems in a University of Oxford study that raises expectations about the diabetes drug’s ...